Mazahir Alimohamed
Stock Analyst at Oppenheimer
(2.14)
# 3,141
Out of 4,534 analysts
9
Total ratings
62.5%
Success rate
4.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mazahir Alimohamed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals | Maintained: Buy | $97 | $56.25 | +72.44% | 1 | Jul 14, 2026 | |
| CNTB Connect Biopharma Holdings | Initiated Coverage: Buy | $8 | $2.20 | +263.64% | 1 | Jul 9, 2026 | |
| EWTX Edgewise Therapeutics | Initiated Coverage: Buy | $51 | $38.81 | +31.41% | 1 | Jul 9, 2026 | |
| IFRX InflaRx | Reiterated: Buy | $5 → $9 | $1.82 | +394.51% | 2 | Jun 30, 2026 | |
| BBOT BridgeBio Oncology Therapeutics | Initiated Coverage: Buy | $22 | $8.42 | +161.28% | 2 | Jun 22, 2026 | |
| TYRA Tyra Biosciences | Maintained: Buy | $50 | $31.06 | +61.00% | 1 | Jun 17, 2026 | |
| IKT Inhibikase Therapeutics | Initiated Coverage: Buy | $5 | $2.23 | +124.22% | 1 | Jun 10, 2026 |
Tarsus Pharmaceuticals
Jul 14, 2026
Maintained: Buy
Price Target: $97
Current: $56.25
Upside: +72.44%
Connect Biopharma Holdings
Jul 9, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $2.20
Upside: +263.64%
Edgewise Therapeutics
Jul 9, 2026
Initiated Coverage: Buy
Price Target: $51
Current: $38.81
Upside: +31.41%
InflaRx
Jun 30, 2026
Reiterated: Buy
Price Target: $5 → $9
Current: $1.82
Upside: +394.51%
BridgeBio Oncology Therapeutics
Jun 22, 2026
Initiated Coverage: Buy
Price Target: $22
Current: $8.42
Upside: +161.28%
Tyra Biosciences
Jun 17, 2026
Maintained: Buy
Price Target: $50
Current: $31.06
Upside: +61.00%
Inhibikase Therapeutics
Jun 10, 2026
Initiated Coverage: Buy
Price Target: $5
Current: $2.23
Upside: +124.22%